Transcode Therapeutics Leadership Change
Thomas A. Fitzgerald resigned as CFO and Director of TransCode Therapeutics effective September 9, 2026. The company entered into a separation agreement providing for up to $1.25 million in severance payments, accelerated vesting of existing equity, and a new grant of 185,000 stock options. A portion of the cash severance and option vesting is contingent on the company achieving specific funding thresholds of $5 million and $10 million.
- Counterparty
- Thomas A. Fitzgerald
- Term
- 12 months